Receive email when new articles are published onSeveral new clinical trials in prostate cancer have started recruiting in recent months. Maybe one of your patients could benefit from enrolling?Adults with this diagnosis may be interested in a randomized, double-blind, phase 3 study examining whether an experimental poly polymerase inhibitor called saruparib can further delay disease progression when added to a next-generation hormonal agent such as abiraterone , darolutamide , or enzalutamide .
MK-5684 is designed to inhibit the CYP11A1 enzyme, thereby disrupting the androgen-receptor signaling pathway. Like the trial described above, all patients will remain on their respective therapy until disease progression. In this trial, one group will take twice-daily tablets of MK-5684 without hormone replacement therapy but the same mix of oral dexamethasone and fludrocortisone. Rescue hydrocortisone will also be available. The second group will be assigned either enzalutamide or abiraterone plus prednisone.
In the trial, half of participants will undergo five treatments of SBRT over 2 weeks, while the other half will receive 20-45 treatments of EBRT over 4-9 weeks. Study sites in 14 US states began recruiting the trial's 1209 participants in November 2023. Metastasis-free survival over 15 years is the primary endpoint, overall survival is a secondary endpoint, and QoL measures, apart from fatigue, will not be tracked.